Details and outcomes of the 3 DLBCL patients with HCV-RNA below threshold level before immunochemotherapy
| Case . | Age, y . | Sex . | HCV-RNA level, KIU/mL . | AST/ALT, IU/L . | Outcome/follow-up time, (mo) . | ||||
|---|---|---|---|---|---|---|---|---|---|
| At baseline . | Peak level during treatment . | At last evaluation . | At baseline . | Peak level during treatment . | At last evaluation . | ||||
| 1 | 59 | M | < 5 | 3960 | 79 | 19/12 | 212/71 | 44/18 | Alive/6 |
| 2 | 77 | F | < 5 | 1200 | < 5 | 40/15 | 156/125 | 33/34 | Alive/28 |
| 3 | 74 | F | < 5 | 590 | 270 | 50/29 | 274/302 | 34/29 | Alive/28 |
| Case . | Age, y . | Sex . | HCV-RNA level, KIU/mL . | AST/ALT, IU/L . | Outcome/follow-up time, (mo) . | ||||
|---|---|---|---|---|---|---|---|---|---|
| At baseline . | Peak level during treatment . | At last evaluation . | At baseline . | Peak level during treatment . | At last evaluation . | ||||
| 1 | 59 | M | < 5 | 3960 | 79 | 19/12 | 212/71 | 44/18 | Alive/6 |
| 2 | 77 | F | < 5 | 1200 | < 5 | 40/15 | 156/125 | 33/34 | Alive/28 |
| 3 | 74 | F | < 5 | 590 | 270 | 50/29 | 274/302 | 34/29 | Alive/28 |